Innovance vwf ac

Patient serum was drawn on day 1, 4 and 7 to measure angiotensin II, cortisone, cortisol and aldosterone levels. Patient citrated plasma was used to measure VWF and D-Dimer. All assays were performed according to the manufacturer’s instructions. Concentrations were calculated against standard curves and used for statistical analysis. Blood glucose was measured by glucometer (Glucocare Sense, RMD Mediaids ltd, Haryana, India) and sodium, urea and potassium were measured as part of routine clinical care.
The circulating blood biomarkers were assayed using the following kits: Angiotensin II Enzyme-linked Immunosorbent Assay (ELISA) (E13652287, Sincere Biotech Co.,Ltd, New Taipei City 221, Taiwan (R.O.C.)); Cortisone ELISA (E13652408, Sincere Biotech Co.,Ltd, Sincere Biotech Co.,Ltd, New Taipei City 221, Taiwan (R.O.C.)); Architect Cortisol chemiluminescent microparticle immunoassay (CMIA) (8D15-25, Abbott Laboratories, Abbott Park, Illinois, USA); Liaison Aldosterone chemiluminescent immunoassay (CLIA) (310,450, DiaSorin, Sallugia, Italy); Innovance VWF:Ac (10,487,040/OPHL03, Siemens Healthcare Diagnostics, Marburg, Germany); and Tina-quant D-Dimer Gen.2 particle-enhanced immunoturbidimetric assay (04,912,551, Roche Diagnostics GmbH, Mannheim, Germany).

Within the following 24 h after admission, venous blood samples were drawn from all patients and centrifuged at 1200 × g for 15 min within 2 h of collection and subsequently stored at −80°C for further analysis. VWF activity (Innovance VWFAc, Siemens, Spain), MMP-10 levels (R&D Systems, USA), and TAFI activity (TAFIa, STA STACHROM TAFI, Stago, France) were measured with an automated ELISA analyzer TRITURUS (Grifols, Spain) in citrated plasma samples after being thawed on ice and thoroughly vortexed. The detection limit of the assays was 2.2%, 15.1 pg/ml, and 5% for VWFAc, MMP-10, and TAFIa, respectively. All experiments were performed and analyzed in a blinded manner.